secwatch.observer — SEC 8-K summary
======================================

Issuer:     vTv Therapeutics Inc. (VTVT)
CIK:        0001641489
Form:       8-K
Filed at:   2025-11-06T23:59:59+00:00
Accession:  0001641489-25-000058
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

vTv Therapeutics Q3 net loss $8.7M; Phase 3 CATT1 data expected H2 2026
-----------------------------------------------------------------------

- Net loss $8.7M ($1.08 per share) vs $4.8M loss ($0.88) in Q3 2024.
- Cash $98.5M at Sept 30, 2025, up from $36.7M at Dec 31, 2024, after $80M private placement.
- First patient randomized in Phase 3 CATT1 trial of cadisegliatin; topline data H2 2026.
- U.S. patent allowed for crystalline salt forms of cadisegliatin; exclusivity through 2041.
- R&D expenses $7.0M, more than double Q3 2024, due to cadisegliatin spend and milestone accrual.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1641489/000164148925000058/0001641489-25-000058-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1641489/000164148925000058/vtvt-20251106.htm
  HTML page:      https://secwatch.observer/filing/0001641489-25-000058

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer